Kala Bio (KALA) Non-Current Deferred Tax Liability (2017 - 2024)
Kala Bio (KALA) posted Non-Current Deferred Tax Liability of $499000.0 for Q4 2024, down 21.79% sequentially from $638000.0 in Q4 2023, and down 21.79% YoY from $638000.0 in Q1 2024.
Kala Bio (KALA) Non-Current Deferred Tax Liability (2017 - 2024) Analysis & Trends
Kala Bio has reported Non-Current Deferred Tax Liability for 8 years, with the latest figure at $499000.0 in Q4 2024.
- Quarterly Non-Current Deferred Tax Liability fell 21.79% year-over-year to $499000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $499000.0 (down 21.79% YoY) and the FY2024 annual result came in at $499000.0, down 21.79% from the prior year.
- Non-Current Deferred Tax Liability eased to $499000.0 in Q4 2024 per KALA's latest filing, from $638000.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $7.8 million in Q4 2020 and troughed at $4000.0 in Q4 2022.
- A 5-year average of $1.9 million and a median of $499000.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability plunged 98.79% in 2022, then surged 15850.0% in 2023.
- Over 5 years, Non-Current Deferred Tax Liability stood at $7.8 million in 2020, then tumbled by 95.76% to $331000.0 in 2021, then slumped by 98.79% to $4000.0 in 2022, then soared by 15850.0% to $638000.0 in 2023, then decreased by 21.79% to $499000.0 in 2024.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $499000.0, $638000.0, and $4000.0 for Q4 2024, Q4 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 499,000.00 |
| Dec 31, 2024 | 499,000.00 |
| Dec 31, 2023 | 638,000.00 |
| Dec 31, 2023 | 638,000.00 |
| Dec 31, 2022 | 4,000.00 |
| Dec 31, 2022 | 4,000.00 |
| Dec 31, 2021 | 331,000.00 |
| Dec 31, 2021 | 331,000.00 |
| Dec 31, 2020 | 7.81 Mn |
| Dec 31, 2020 | 7.81 Mn |
| Dec 31, 2019 | 9.18 Mn |
| Dec 31, 2019 | 9.18 Mn |
| Dec 31, 2018 | 8.22 Mn |
| Dec 31, 2018 | 8.22 Mn |
| Dec 31, 2017 | 9,000.00 |
| Dec 31, 2017 | 9,000.00 |